Focused On-demand Library for Homeobox protein DLX-4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q92988

UPID:

DLX4_HUMAN

Alternative names:

Beta protein 1; Homeobox protein DLX-7; Homeobox protein DLX-8

Alternative UPACC:

Q92988; D3DTX2; D3DTX3; O60480; Q13265; Q6PJK0; Q9HBE0

Background:

Homeobox protein DLX-4, also known as Beta protein 1, Homeobox protein DLX-7, and DLX-8, plays a crucial role in embryonic development, particularly in palatogenesis. It is implicated in the regulation of hemoglobin S production and acts as a repressor. Its involvement in developmental processes underscores its importance in cellular differentiation and tissue formation.

Therapeutic significance:

The protein's association with Non-syndromic orofacial cleft 15, a condition characterized by cleft lips with or without cleft palate, highlights its potential as a target for therapeutic intervention. Understanding the role of Homeobox protein DLX-4 could open doors to potential therapeutic strategies for managing and treating orofacial defects.